MCED testing: A paradigm shift in early cancer detection
April 18 | 12:30 pm – 1:30 pm ET
Spotlight Theater B | Presented by Exact Sciences
Early cancer detection can help save lives, yet gaps in cancer screening exist. As such, cancer remains the second-leading cause of death in the U.S. and is projected to reach #1 by 2030. MCED blood tests designed to detect a variety of tumor markers associated with multiple cancer types are being developed to help detect cancer prior to symptom onset. An innovative multi-biomarker class MCED test in development shows promise in early cancer detection. As part of routine care, it may help shift the paradigm in cancer screening and help reduce its burden.
This Exhibitor Spotlight Theater is a promotional activity and is not approved for continuing education credit. The content of this Exhibitor Spotlight Theater and opinions expressed by presenters are those of the sponsor or presenter and are not of the American Association for Cancer Research® (AACR).